Aug 16, 2022 | Press Releases
“The rebate rule came out of a concern about rising drug prices,” said Brill. “But it is a policy that is chock full of unintended consequences. If it were implemented, we’d have fewer discounts. That’s definitely not going to lower overall spending in the healthcare sector.”
May 12, 2022 | Analysis
In response to the FTC’s request for information regarding the business practices of pharmacy benefit managers (PBMs) and their impact on pharmacies and consumers, MGA’s Alex Brill submitted a letter detailing his findings.
Feb 12, 2021 | News
This week, three publications in the healthcare policy and regulatory affairs industries referenced MGA’s recent report on the potential savings from accelerating US approval of complex generics.
Feb 9, 2021 | Analysis
Matrix Global Advisors (MGA) today released a new report, “Potential Savings from Accelerating US Approval of Complex Generics,” by MGA founder and CEO Alex Brill.
Sep 22, 2020 | News
“The report finds that extending patents on just those five drugs [Prilosec, TriCor, Suboxone, Doryx, and Namenda] will result in a cost to the U.S. health care system of $4.7 billion annually—money that in theory could have been saved if the drugs had been available in a generic form.”